GlassScriptPhysician profile
Lynetta L Stiltner
NPI 1619081502
$2,417.48
in general payments reported to CMS, 2019-2025
28 companies · $997 in 2025
The $997 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $19.08 · 2021: $194 · 2022: $384 · 2023: $397 · 2024: $206 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,600.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.23 | 2022-2025 | Vraylar |
| Novo Nordisk INC | $348.69 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $335.02 | 2019-2025 | Krystexxa, Evenity |
| Pfizer INC. | $293.40 | 2019-2025 | |
| Exact Sciences Corporation | $160.02 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astellas Pharma US INC | $130.36 | 2022-2023 | Veozah |
| Glaxosmithkline, LLC. | $101.69 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Daiichi Sankyo INC. | $56.49 | 2021-2022 | |
| Lilly USA, LLC | $53.31 | 2021-2024 | Mounjaro, Emgality, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $50.68 | 2022 | |
| Janssen Pharmaceuticals, INC | $39.85 | 2019-2022 | |
| Abbott Laboratories | $36.58 | 2023-2024 | Freestyle Libre 3 |
| Abiomed | $32.29 | 2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.81 | 2022 | |
| Merck Sharp & Dohme LLC | $29.74 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $29.15 | 2021 | |
| Shield Therapeutics INC | $22.71 | 2025 | |
| Valeritas, INC. | $22.13 | 2019 | |
| Terumo Medical Corporation | $19.08 | 2020 | |
| Esperion Therapeutics, INC. | $18.73 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.34 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $16.84 | 2025 | Voquezna |
| Allergan, INC. | $16.42 | 2019 | |
| Xeris Pharmaceuticals, INC. | $16.25 | 2021 | |
| Dexcom, INC. | $14.37 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.35 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.31 | 2022 | |
| Genentech USA, INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynetta Stiltner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.